Flagship Ventures Management

Latest statistics and disclosures from Flagship Pioneering's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are MRNA, SANA, OMGA, FHTX, DNLI, and represent 96.80% of Flagship Pioneering's stock portfolio.
  • Added to shares of these 1 stock: SYRS.
  • Reduced shares in these 3 stocks: EVLO (-$31M), Axcella Health (-$12M), DNLI (-$6.4M).
  • Sold out of its positions in Axcella Health, EVLO.
  • Flagship Pioneering was a net seller of stock by $-47M.
  • Flagship Pioneering has $1.3B in assets under management (AUM), dropping by -3.81%.
  • Central Index Key (CIK): 0001400240

Tip: Access up to 7 years of quarterly data

Positions held by Flagship Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Flagship Pioneering

Flagship Pioneering holds 7 positions in its portfolio as reported in the December 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Moderna (MRNA) 72.5 $961M 9.7M 99.45
 View chart
Sana Biotechnology (SANA) 7.7 $102M 25M 4.08
 View chart
Omega Therapeutics (OMGA) 6.6 $88M 29M 3.01
 View chart
Foghorn Therapeutics (FHTX) 6.2 $82M 13M 6.45
 View chart
Denali Therapeutics (DNLI) 3.8 $50M -11% 2.3M 21.46
 View chart
Seres Therapeutics (MCRB) 2.4 $32M 23M 1.40
 View chart
Syros Pharmaceuticals (SYRS) 0.8 $10M +30% 1.3M 7.79
 View chart

Past Filings by Flagship Pioneering

SEC 13F filings are viewable for Flagship Pioneering going back to 2016

View all past filings